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Abstract
Introduction: The diagnostic and prognostic value of arterial blood gas analysis (ABGA) parameters in unselected
patients presenting with acute dyspnea to the Emergency Department (ED) is largely unknown.
Methods: We performed a post-hoc analysis of two different prospective studies to investigate the diagnostic and
prognostic value of ABGA parameters in patients presenting to the ED with acute dyspnea.
Results: We enrolled 530 patients (median age 74 years). ABGA parameters were neither useful to distinguish
between patients with pulmonary disorders and other causes of dyspnea nor to identify specific disorders
responsible for dyspnea. Only in patients with hyperventilation from anxiety disorder, the diagnostic accuracy of pH
and hypoxemia rendered valuable with an area under the receiver operating characteristics curve (AUC) of 0.86.
Patients in the lowest pH tertile more often required admission to intensive care unit (28% vs 12% in the first
tertile, P < 0.001) and had higher in-hospital (14% vs 5%, P = 0.003) and 30-day mortality (17% vs 7%, P = 0.002).
Cumulative mortality rate was higher in the first (37%), than in the second (28%), and the third tertile (23%, P =
0.005) during 12 months follow-up. pH at presentation was an independent predictor of 12-month mortality in
multivariable Cox proportional hazard analysis both for patients with pulmonary (P = 0.043) and non-pulmonary
disorders (P = 0.038).
Conclusions: ABGA parameters provide limited diagnostic value in patients with acute dyspnea, but pH is an
independent predictor of 12 months mortality.
Introduction
Patients presenting to the emergency department (ED)
with acute dyspnea require a rapid diagnostic work up to
decide whether hospitalization or intensive care admission
are needed and to guide further therapy [1]. Acute heart
failure (AHF), exacerbation of chronic obstructive pul-
monary disease (COPD), and pneumonia account for the
majority of emergency consultations by patients with
acute dyspnea [2,3]. As dyspnea is not a specific symptom,
the rapid and accurate identification of the underlying
causes remains a clinical challenge. Misdiagnosis causes
morbidity and increases time to discharge and treatment
cost [4]. In addition, treatment for one common disorder,
e.g. AHF, might even be hazardous for patients with other
conditions such as exacerbated COPD or pneumonia [5].
At presentation to the ED, arterial blood gas analysis
(ABGA) is often performed in dyspneic patients to assess
acid-base disturbances, and to diagnose and quantify
respiratory insufficiency. Accordingly, it has been recom-
mended for the clinical work-up in several dyspnea-
related diseases [6-9]. Several studies have investigated
the value of ABGA in patients with suspected pulmonary
embolism (PE) [10-12], but the usefulness of the different
prediction rules proposed by theses studies has been
questioned [13]. In patients with community-acquired
pneumonia (CAP), Levin et al. examined factors asso-
ciated with the use of ABGA and also assessed whether
measurement of ABGA in patients was associated with
hospitalization, ICU treatment, or death [14]. * Correspondence: MuellerChr@uhbs.ch
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dyspnea, however, is poorly studied. Specifically, it is
unknown whether ABGA parameters can be used as a
diagnostic marker in patients with a non-specific symp-
tom such as acute dyspnea. Additionally, it should be
further investigated whether the prognostic value of
ABGA parameters observed in patients with exacerbated
COPD and pneumonia can be expanded to unselected
patients with acute dyspnea.
The aim of this study was to prospectively investigate
the value of ABGA parameters as biological markers for
diagnosis and prognosis in patients presenting to the ED
with acute dyspnea.
Materials and methods
Setting and study population
In this prospective observational study, we investigated
patients presenting to the ED of the University Hospital
Basel, Switzerland, with acute dyspnea. If several symp-
toms were present, dyspnea had to be the primary com-
plaint. The interdisciplinary ED manages around 40,000
patients per year. It is an independent department with
its own senior staff and rotating physicians from both the
internal medicine department and surgery department.
A total of 1,135 patients were enrolled in two series of
consecutive patients: 452 patients (out of 665 patients
screened) were enrolled from May 2001 to April 2002 in
t h eB - t y p en a t r i u r e t i cp e p t i d ef o rA c u t eS h o r t n e s so f
Breath Evaluation (BASEL) study [2], and another 683
patients (of 765 patients screened) were enrolled between
April 2006 and March 2008. Patient recruitment had to
be paused between 2003 and 2005 due to a lack of
resources. Exclusion criteria were identical during both
recruitment periods: age younger than 18 years, an
obvious traumatic cause of dyspnea, cardiogenic shock,
severe renal disease (defined as serum creatinine level of
more than 250 μmol/l in the first series and by hemodia-
lysis in the second period). Patients were enrolled by a
study physician who was otherwise not involved in the
clinical management of the individual patient. Of the
1,153 patients enrolled, 530 had ABGA at presentation
and were considered as the study population. The study
was carried out according to the principles of the
Declaration of Helsinki and approved by the local ethical
committee. Written informed consent was obtained from
all participants prior to study entry.
Adjudication of the final diagnosis
After patient discharge from the hospital, the final diag-
nosis was independently adjudicated in a blinded fashion
by two internal medicine specialists who were not
involved in the care of the patients during the hospitali-
zation according to current recommendations on the
basis of available medical records, including B-type
natriuretic peptide (BNP) levels, the results of all diag-
nostic investigations, the response to treatment, and
autopsy data in those patients who died [1,8,15]. The
physicians adjudicated the final diagnosis by choosing
one or more diagnoses from a pre-specified list that
included the following items: AHF, exacerbated COPD/
asthma, CAP/bronchitis, PE, hyperventilation from anxi-
ety disorder (HV), other, or unknown. If more than one
cause for acute dyspnea was identified, the leading disor-
der responsible for the current episode of acute dyspnea
was determined. When there was disagreement about the
final diagnosis, cases were reviewed and adjudicated in
conjunction with a third internal medicine specialist who
was considered an expert in the field.
Blood sampling and laboratory methods
All patients underwent an initial clinical assessment that
included history taking, a physical examination, non-
invasive blood pressure measurement, 12-lead ECG, con-
tinuous ECG-monitoring, pulse oximetry, standard blood
tests, and chest radiography. ABGA samples were taken
immediately after presentation to the ED after the initial
assessment from the attending physician. If multiple sam-
ples were taken, only values from the first were included
in the analysis. The decision to perform ABGA was made
solely by the physician in charge, based on clinical
grounds. If oxygen supply had been started prior to hos-
pital entry, it was stopped for at least two minutes before
collection of the sample. For ABGA, a 1 ml arterial speci-
men of blood was collected from a radial artery into
heparinized syringes and immediately analyzed using the
Radiometer ABL™ 700 (Radiometer Medical ApS,
Copenhagen, Denmark). The analysis included measure-
ment of pH, the partial pressure of arterial carbon diox-
ide (PaCO2), and the partial pressure of arterial oxygen
(PaO2) based on ion-selective electrodes with potentio-
metric measurement for pH and PaCO2,a n da m p e r o -
metric measurement of PaO2. Standard bicarbonate
(HCO3) was calculated from the observation parameters
pH and PaCO2. The Radiometer ABL™ 700 has a high
accuracy and repeatability (precision within run: pH
0.0020, for PaCO2 0.40 mmHg, and PaO2 0.9 mmHg;
precision between run: pH 0.0084, PaCO2 0.66 mmHg,
and PaO2 1.5 mmHg). Values of PaO2 above 10.8 kPa,
PaCO2 4.7 to 6.1 kPa, pH 7.35 to 7.45, and HCO3 21 to
26 mmol/l were considered within normal ranges. To cal-
culate the estimated glomerular filtration rate the abbre-
viated 4-variable Modification of Diet in Renal Disease
study equation was used.
Endpoints and follow up
The diagnostic value of ABGA variables was assessed in
comparison to the adjudicated gold standard diagnosis.
The prospective value of ABGA variables was assessed
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in-hospital mortality, and 30-day mortality, as well as
for long-term outcome. All patients were contacted by
telephone interview performed by trained researchers
blinded to the results of laboratory testing. In case of
uncertainties regarding vital status, referring physicians
and administrative database of the respective hometown
were contacted.
Statistical analysis
Categorical variables are presented as numbers and per-
centage, continuous variables as mean ± standard devia-
tion (SD) or median and 95% confidence interval (95%
CI) or interquartile range (IQR). Comparisons were
made using the Student’s t-test, Mann-Whitney U test,
Wilcoxon test, and Kruskal-Wallis test for numerical
parameters and the chi-square test for categorical data
where appropriate. Stepwise multiple logistic regression
analysis was used to identify ABGA parameters that
were independently correlated to a defined endpoint.
HCO3 values were calculated from pH and PaCO2 and
therefore not included in the regression model. (ROC)
operating characteristics curves were calculated to deter-
mine the sensitivities, specificities, likelihood ratios, and
predictive values for all independent ABGA parameters.
Kaplan-Meier analysis was performed for survival and
log-rank values to assess statistical significance. We used
Cox proportional hazard models adjusted for age, sex,
New York Heart Association (NYHA) class, history of
coronary artery disease, COPD, any pulmonary disease
or chronic kidney disease, smoking status, previous use
of oral diuretics or inhaled beta agonists, systolic blood
pressure, respiration rate, body mass index (BMI), more
than one cause of dyspnea and pH at admission to com-
pute hazard ratios (HR) and 95% CI of predictors of 12-
month mortality. All hypothesis testing was two-tailed,
and a P-value of 0.05 was considered statistically signifi-
cant. Analyses were performed using SPSS (Release
19.0.0, SPSS Inc., Chicago, IL, USA) and MedCalc for
Windows (Version 11.4.4, Mariakerke, Belgium).
Results
Characteristics of study population
Among the study population (n = 530), AHF was the adju-
dicated diagnosis in 206 patients (39%). Among the non-
cardiac causes of dyspnea, exacerbated COPD/asthma was
present in 118 patients (22%), CAP/bronchitis in 94
patients (18%), PE in 28 patients (5.3%), HV in 18 patients
(3.4%), and other causes such as pneumothorax, malig-
nancy, interstitial lung disease, or anemia in 66 patients
(13%). In 11 patients (2.1%), the diagnostic work up was
insufficient to adjudicate a diagnosis. One hundred and
fourteen patients (22%) presented with more than one
cause responsible for acute dyspnea. Among those,
56 patients (49%) had multiple pulmonary disorders.
Patients in the study population more often were male,
were obese, presented with higher NYHA class, were
current or former smokers, had a history of a pulmonary
disease and accordingly more frequently used inhaled beta
agonists and inhaled and oral steroids, more often had
clinical signs of respiratory tract infection, had lower
oxygen saturation rates, and lower BNP values. In the
study population, patients more often suffered from exa-
cerbated COPD, asthma, bronchitis, or pneumonia and
more often were admitted to the hospital and to ICU. The
detailed baseline characteristics are summarized in the
supplemental digital content in Additional file 1.
Diagnostic accuracy of arterial blood gas parameters
Values of ABGA parameters at presentation varied
widely in all underlying disorders (Figure 1). Acidosis
(pH < 7.35) was found in 88 patients (17%) at presenta-
tion. Of those, 9 (10%) had metabolic acidosis, 66 (75%)
respiratory acidosis, and 13 (15%) mixed-type acidosis.
In 142 patients (27%) alkalosis (pH > 7.45) was present
at presentation. Six patients (3.4%) showed metabolic,
108 (60%) respiratory, and 65 (36%) mixed-type alkalo-
sis. Hypoxemia (PaO2 < 10.8 kPa) was found in 377
patients (71%).
Evaluating the value of AGBA parameters at presenta-
tion as a diagnostic test, we found that neither the pre-
sence of respiratory or metabolic acidosis or alkalosis
nor individual or combined absolute values of ABGA
parameters were able to reliably identify specific disor-
ders responsible for dyspnea or to distinguish patients
with pulmonary disorders from other causes of dyspnea
(Table 1). Only in patients with hyperventilation from
anxiety disorders, pH (odds ratio (OR) 4.50, 95% CI 2.27
to 8.92) and hypoxemia (OR 0.21, 95% CI 0.07 to 0.65)
provided useful diagnostic information. We found a
combined area under the curve of 0.86 (95% CI 0.82 to
0.88) with an optimal cut-off for pH of 7.45. Using this
cut-off, pH yielded a sensitivity and specificity of 72%
and 75%, respectively. When subgroups of patients with
NYHA III/IV (n = 471, 89%), or with oxygen saturation
below 90% (n = 117, 23%) were analyzed separately, the
diagnostic accuracy did not increase.
Value of ABGA parameters to predict admission to ICU
Of the study population (n = 530), 91 patients (17%, AHF
= 46, exacerbated COPD/asthma = 14, CAP/bronchitis =
14, PE = 5, and others = 12) were admitted to the ICU.
Patients admitted to the ICU had lower pH (7.39 (IQR
7.28 to 7.49) vs. 7.43 (7.39 to 7.52), P < 0.01) and higher
PaCO2 levels (5.5 kPa (IQR 4.5 to 11) vs. 5.2 kPa (IQR
4.4 to 7.8), P < 0.01) than patients not admitted. The pre-
valence of respiratory acidosis with hypoxemia was
higher in patients admitted to ICU (20 of 91 patients,
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patients, 6.6%, P < 0.001). Multivariable logistic regres-
sion analysis identified pH as an independent ABGA
parameter to predict ICU admission with an OR of 0.55
for every increase of pH of 0.1 (Table 2). From ROC ana-
lysis (area under curve 0.65, 95% CI 0.61 to 0.69), a pH
less than 7.33 had a high specificity (90%) but low sensi-
tivity (37%) to identify those patients in need for ICU
care. The negative predictive value was 87%.
Predictive value of pH at presentation for short-term
outcome
The distribution of several baseline characteristics dif-
fered among the three groups stratified according to ter-
tiles of pH (intertertile range 7.40 to 7.44; Table 3).
Patients in the first tertile, with the lowest pH levels (pH
≤7.39), more often were current smokers, more often
showed signs of decompensated heart failure, had higher
respiration rates, had lower C-reactive protein levels, and
presented with lower oxygen saturation at presentation.
Four hundred and sixty-two patients (87%) were
admitted to the hospital. Table 4 shows that patients in
the first tertile more often required admission to the ICU
(28% vs 12% in the second, P < 0.001, and third tertile,
P < 0.001), had a higher in-hospital mortality (14% vs 5%
in the second, P = 0.002, and third tertile, P = 0.003), and
a higher mortality after 30 days (17% vs 7% in the second,
P = 0.002, and third tertile, P = 0.002).
Predictive value of pH at presentation for long-term
outcome
During a median length of follow up of 425 (IQR 374 to
739) days in survivors, there were 175 deaths (33%) and
a median time to death of 93 (20 to 211) days. After 12
months, 152 patients (29%) had died. Analysis based on
pH at presentation showed a higher 12-month mortality
Figure 1 Values of arterial blood gas parameters at presentation. Boxplots (median, interquartile range) of pH (upper left), partial pressure of
arterial carbon dioxide (PaCO2; upper right), partial pressure of arterial oxygen (PaO2; lower left), and partial pressure of bicarbonate (HCO3; lower
right) at presentation in patients with acute heart failue (AHF), excerbated chronic obstructive pulmonary disease or asthma (ECOPD/asthma),
community-acquired pneumonia (CAP), pulmonary embolism (PE), hyperventilation from anxiety (HV), and other disorders.
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ond (28%) and third tertiles (23%, P = 0.005 by log-rank
test; Figure 2). When analyzed according to the underly-
ing disease, mortality in the first tertile remained higher
both in patients with non-pulmonary causes of dyspnea
(P = 0.040) and in patients with either exacerbated
COPD/asthma or CAP/bronchitis (P = 0.005), respec-
tively. Overall, mortality after 12-month follow-up was
higher in patients with non-pulmonary causes of dys-
pnea (32% against 23%, P = 0.034). In patients who pre-
sented with more than one disorder responsible for
dyspnea (41% against 25%, P = 0.008), 12-month mortal-
ity rates stratified by tertiles of pH were higher in the
first tertile (n = 33, 60% (standard error (SE) 8.5), P <
0.001 by log-rank) and second tertile (n = 43, 44% (SE
7.6), P = 0.034) but not in the third tertile (n = 34, 23%
(SE 7.1), P = 0.803; Figure 3).
Multivariable analysis showed that pH at presentation
independently predicted 12-month mortality (HR 1.41,
95% CI, 1.11 to 1.79 for decrease of pH of 0.1, P =
0.005) in all studied patients presenting with acute dys-
pnea. Other independent predictors were previous use
of oral diuretics, BMI and two or more causes of acute
dyspnea. (Table 5). When analyses were repeated
according to the underlying disorder, pH at presentation
remained independent in the multivariable model in
both patients with non-pulmonary (HR 1.41, 95% CI
1.02 to 1.92, P = 0.038) and pulmonary causes of dys-
pnea (HR 1.59, 95% CI 0.99 to 1.14, P = 0.043).
Subgroup analysis in patients with lactate values
available
Lactate values were available in 298 patients (52%). In
this subgroup, lactate was a significant predictor of diag-
nosis only in patients with AHF (OR 1.25, 95% CI 1.01
to 1.55; area under curve 0.573, 95% CI 0.51 to 0.63). As
Table 1 Diagnostic value of ABGA parameters to identify
disorders responsible for acute dyspnea (only significant
variables)
Variable OR (95% CI) AUC
(95% CI)
Acute heart failure pH 0.58 (0.44-0.77) 0.615
(0.57-0.66)
PaCO2 0.81 (0.69-0.95)
Exacerbated COPD
or asthma
pH 1.64 (1.14-2.37) 0.670
(0.63-0.71)
PaCO2 1.44 (1.20-1.73)
Hypoxemia 1.71 (1.04-2.82)
Pulmonary
embolism
PaCO2 0.61 (0.44-0.85) 0.678
(0.64-0.72)
Pneumonia or
bronchitis
Hypoxemia 1.84 (1.07-3.17) 0.558
(0.51-0.60)
Anxiety disorder pH 4.50 (2.27-8.92) 0.855
(0.82-0.88)
Hypoxemia 0.21 (0.07-0.65)
Pulmonary disorder pH 1.40 (1.06-1.87) 0.639
(0.60-0.66)
PaCO2 1.31 (1.12-1.54)
Hypoxemia 2.01 (1.37-3.13)
Multivariable logistic regression analysis. Odds ratios (OR) with 95%
confidence interval (95% CI) for independent arterial blood gas analysis
(ABGA) parameters; Categorial variables included in the model were
hypoxemia, metabolic acidosis or alkalosis, respiratory acidosis or alkalosis,
mixed-type alkalosis or acidosis, pH, partial pressure of arterial carbon dioxide
(PaCO2), and partial pressure of arterial oxygen (PaO2). OR are given for any
increase of 1 kPa for PaO2 or PaCO2, and 0.1 for pH. Area under the curve
(AUC) quantifying the diagnostic accuracy of the individual variables in
settings with only one significant diagnostic ABGA variable (pulmonary
embolism and community-acquired pneumonia), and for the optimal
combination of ABGA variables in settings with more than one significant
variables (all others). COPD, chronic obstructive pulmonary disease.
Table 2 Prognostic value of ABGA parameters to predict
short-term and long-term outcome
ICU admission OR 95% CI AUC 95% CI P-value
pH 0.552 0.43-0.71 0.647 0.61-0.69 < 0.001
PaCO2 1.309 1.15-1.50 0.591 0.55-0.63 0.001
PaO2 1.029 0.98-1.08 0.476 0.43-0.52 0.257
HCO3 1.00 0.96-1.05 0.504 0.46-0.55 0.956
Base excess 0.954 0.91-1.00 0.541 0.50-0.58 0.041
In-hospital mortality OR 95% CI AUC 95% CI P-value
pH 0.645 0.49-0.85 0.647 0.61-0.69 0.022
PaCO2 1.142 0.96-1.35 0.526 0.48-0.57 0.125
PaO2 1.050 1.00-1.11 0.576 0.53-0.62 0.133
HCO3 0.960 0.90-1.02 0.528 0.49-0.57 0.191
Base excess 0.943 0.89-1.00 0.546 0.50-0.59 0.045
30 days mortality OR 95% CI AUC 95% CI P-value
pH 0.602 0.46-0.79 0.650 0.61-0.69 < 0.001
PaCO2 1.205 1.04-1.40 0.562 0.52-0.61 0.015
PaO2 1.025 0.97-1.09 0.486 0.44-0.53 0.409
HCO3 0.977 0.92-1.03 0.504 0.46-0.55 0.416
Base excess 0.950 0.90-1.00 0.518 0.47-0.56 0.067
12-month mortality OR 95% CI AUC 95% CI P-value
pH 0.767 0.62-0.94 0.584 0.54-0.63 0.011
PaCO2 1.160 1.03-1.30 0.577 0.53-0.62 0.012
PaO2 1.040 1.00-1.09 0.518 0.47-0.56 0.071
HCO3 1.021 0.98-1.06 0.544 0.50-0.59 0.298
Base excess 1.022 0.98-1.06 0.559 0.52-0.60 0.296
pH OR 95% CI AUC 95% CI P-value
ICU admission 0.533 0.41-0.69 0.661 0.62-0.70 < 0.001
In-hospital mortality 0.621 0.44-0.88 0.662 0.61-0.71 0.007
30-day mortality 0.602 0.46-0.79 0.650 0.61-0.69 < 0.001
12-month mortality 0.767 0.62-0.94 0.584 0.54-0.63 0.011
Univariable logistic regression analysis of arterial blood gas analysis (ABGA)
parameters to predict ICU admission, in-hospital mortality, 30-day mortality,
and 12-month mortality. Multivariable logistic regression analysis of significant
parameters from univariable analysis shows pH as independent predictor.
Odds ratios (OR) with 95% confidence interval (95% CI) for ABGA parameters;
OR are given for any increase of 1 kPa for partial pressure of arterial carbon
dioxide (PaCO2), and partial pressure of arterial oxygen (PaO2), partial pressure
of bicarbonate (HCO3), base excess and 0.1 for pH. Area under the curve
(AUC) quantifying the diagnostic accuracy of the individual ABGA variables.
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Variable pH ≤7.39
(n = 174)
pH 7.40- 7.44
(n = 177)
pH ≥7.45
(n = 179)
P-value
Age, years 74 (64-81) 74 (64-82) 75 (64-81) 0.99
Male sex, n (%) 62 (64) 80 (45) 75 (42) 0.18
Medical History, n (%)
Coronary heart disease 76 (44) 67 (38) 65 (36) 0.33
Arterial hypertension 106 (61) 119 (67) 106 (59) 0.26
Stroke/peripheral arterial disease 37 (22) 34 (19) 30 (17) 0.53
Chronic obstructive pulmonary disease 80 (46) 85 (48) 72 (40) 0.31
Asthma 7 (4.0) 14 (7.9) 13 (7.3) 0.28
Any pulmonary disease 107 (62) 113 (64) 94 (53) 0.07
Pulmonary embolism 14 (8.0) 20 (11) 15 (8.4) 0.51
Deep venous thrombosis 16 (9.2) 23 (13) 13 (7.3) 0.18
Diabetes mellitus 45 (26) 40 (23) 35 (20) 0.37
Chronic kidney disease 51 (29) 43 (24) 33 (19) 0.06
Depressive disorder 22 (13) 27 (16) 24 (24) 0.69
Malignancy 28 (16) 30 (17) 38 (21) 0.40
Obesity 47 (29) 46 (27) 32 (18) 0.06
Smoking status, n (%) 0.01
never 14 (8.4) 21 (13) 33 (19)
current 73 (44) 54 (32) 56 (31)
former 54 (33) 72 (43) 71 (40)
unknown 25 (15) 20 (12) 17 (9.1)
Symptoms, n (%)
Dyspnea 0.06
NYHA II 12 (6.9) 20 (11) 27 (15)
NYHA III 79 (46) 80 (45) 89 (50)
NYHA IV 83 (48) 77 (44) 63 (35)
Thoracic pain 60 (35) 62 (35) 52 (29) 0.41
Orthopnea 68 (56) 104 (64) 103 (62) 0.61
Weight gain 20 (12) 25 (15) 18 (11) 0.50
Cough 91 (54) 116 (67) 106 (62) 0.04
Expectorant 68 (40) 78 (45) 81 (47) 0.40
Fever (> 38.5°C) 38 (22) 52 (30) 54 (32) 0.11
Medication, n (%)
Diuretics 92 (53) 95 (54) 85 (48) 0.47
Nitrate 22 (13) 21 (12) 20 (11) 0.92
ACE inhibitors, angiotensin receptor blockers 69 (40) 88 (50) 74 (42) 0.14
Beta-blocker 48 (28) 49 (28) 56 (32) 0.67
Aspirin 52 (30) 62 (35) 56 (32) 0.57
Phenprocoumon/LMWH 39 (22) 42 (24) 38 (21) 0.87
Inhaled beta agonists 59 (34) 68 (38) 54 (30) 0.27
Inhaled steroids 46 (26) 47 (36) 54 (30) 0.65
Oral steroids 23 (13) 36 (20) 34 (19) 0.17
Clinical signs, n (%)
Rales 81 (47) 83 (47) 87 (49) 0.92
Wheezing 61 (35) 65 (37) 48 (27) 0.10
Lower extremity edema 68 (39) 70 (40) 61 (34) 0.48
Jugular venous distension 47 (27) 24 (14) 32 (18) 0.01
Hepatojugular reflux 22 (13) 21 (12) 23 (13) 0.98
Vital status
Systolic blood pressure (mmHg) 143 (127-162) 142 (126-165) 136 (122-158) 0.11
Diastolic blood pressure (mmHg) 88 (70-98) 86 (74-96) 82 (73-92) 0.23
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predictor.
Discussion
This prospective study in a large cohort of unselected
patients presenting to the ED with acute dyspnea pro-
vides the following new information. First, ABGA para-
meters at presentation varied widely among patients
with acute dyspnea. Second, used as a diagnostic test,
ABGA parameters were useful neither to distinguish
between patients with pulmonary disorders and other
causes of acute dyspnea nor to identify specific disorders
responsible for acute dyspnea. Acute diseases such as
pulmonary or cardiac disorders seem to have a common
final path leading to hypoxemia, increase of PaCO2, and
increase of base excess irrespective of the original reason
of the disorder. Only in patients with HV did pH and
hypoxemia seem valuable. Third, pH measured at
presentation was a significant predictor of short- and
long-term outcome in dyspneic patients and was, inde-
pendent from other predictors, associated with mortal-
ity, both in patients with pulmonary disorders and other
causes of dyspnea.
These findings are of clinical importance as they ques-
tion the usefulness of ABGA at presentation in patients
presenting with acute dyspnea to the ED. As a diagnos-
tic test, we found ABGA to be of very limited value in
our cohort of dyspneic patients. Evaluating the prognos-
tic value, pH was an independent predictor of mortality
in both patients with pulmonary and other causes of
dyspnea. Patients with a pH level of 7.39 or less showed
a mortality rate after 12 months of 37% in our study
and should receive particular attention. Arterial and/or
venous blood gas analyses are valuable for risk stratifica-
tion in the ED supporting disposition decisions or speci-
fic treatments such as non-invasive ventilation.
Table 3 Baseline characteristics of patients stratified by tertiles of pH (Continued)
Heart rate (beats per minute) 95 (78-110) 96 (82-111) 89 (76-110) 0.12
Respiration rate (breaths per minute) 25 (20-32) 24 (20-30) 22 (18-28) 0.03
Temperature (°C) 37.1 (36.5-37.8) 37.4 (36.7-39.7) 37.4 (36.8-38.0) 0.03
Oxygen saturation (%) 92 (87-96) 96 (92-98) 95 (93-98) < 0.001
Body mass index (kg/m
2) 26.2 (22.8-30.5) 26.3 (22.8-30.6) 25.3 (22.1-28.7) 0.20
Laboratory values
Hemoglobin (g/L) 139 (122-155) 136 (123-150) 136 (125-146) 0.23
Leukocytes (10
9/L) 10.6 (8.0-15.0) 10.0 (8.0-13.2) 10.5 (8.3-13.6) 0.40
C-reactive protein (mg/L) 15 (5-51) 21 (6-80) 27 (7-107) 0.02
Glomerular filtration rate (mL/min/1.73 m
2) 57 (39-86) 64 (46-87) 65 (52-90) 0.06
B-type natriuretic peptide (pg/mL) 305 (93-810) 254 (52-712) 192 (65-760) 0.14
Discharge diagnosis, n (%)
Acute heart failure 81 (47) 65 (37) 60 (34) 0.03
Exacerbation of COPD or asthma 37 (21) 43 (24) 38 (21) 0.73
Pneumonia or bronchitis 29 (17) 32 (18) 33 (18) 0.90
Pulmonary embolism 6 (3.4) 10 (5.6) 12 (6.7) 0.38
Anxiety disorder 1 (0.6) 4 (2.3) 13 (7.3) < 0.001
Others 20 (12) 23 (13) 23 (13) 0.90
ACE, angiotensin-converting enzyme; COPD, chronic obstructive pulmonary disease; LMWH, low molecular weight heparin; NYHA, New York Heart Association.
Data are presented as median and interquartile range, or number of patients (%).
Table 4 Outcome
Variable pH ≤7.39
(n = 174)
pH 7.40-7.44
(n = 177)
pH ≥7.45
(n = 179)
P-value
Initial outcome
Hospital admission, n (%) 158 (91) 151 (85) 153 (86) 0.12
ICU admission, n (%) 48 (28) 21 (12) 22 (12) < 0.001
In-hospital mortality, n (%) 25 (14) 8 (4.5) 9 (5.0) 0.003
Short-term outcome
30-day mortality, n (%) 30 (17) 12 (7.0) 12 (7.0) 0.002
Long-term outcome
Mortality rate at 12 months (%) 37 (3.7) 28 (3.4) 23 (3.2) 0.005
Data are presented as number of patients (%), or cumulative mortality (%) (standard error).
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up of dyspnea-related diseases [6-9]. In exacerbated
COPD, elevated PaCO2 and decreased pH were found
to be independent predictors of hospitalization and
readmission [16,17]. In patients with PE, the diagnostic
value of ABGA has been extensively investigated, as
only around 35% with suspected PE actually do have the
disease [10-12]. Results of these studies have been ques-
tioned for the inability of ABGA to sufficiently exclude
PE, alone or in combination with other clinical data
[ 1 3 ] .A c c o r d i n g l y ,c u r r e n td i agnostic strategies in the
evaluation of suspected PE have focused on probability
scores, d-dimer testing and radiological imaging techni-
ques rather than ABGA parameters [18]. In patients
with unexplained exacerbation of COPD, it has been
suggested that one out of four patients may in fact have
PE [19,20]. A drop of PaCO2 of 0.7 kPa compared with
baseline, together with a history of thromboembolism
and the presence of malignancy have been found to pre-
dict PE in those patients [19]. This study supported ear-
lier findings [21], but contrasted to results of the
Prospective Investigation of Pulmonary Embolism Diag-
nosis (PIOPED) study, that could not identify differences
between patients with and without COPD [22].
Dyspnea results from multiple interactions of signals
in the limbic and autonomic nervous system, the motor
cortex, and peripheral receptors [23]. It is a non-specific
symptom and presents a clinical challenge even for
Figure 2 12-month mortality of patients with acute dyspnea
stratified by tertiles of pH. 12-month mortality in all patients
presenting with dyspnea (n = 530) according to tertiles of pH
measured at presentation.
Figure 3 12-month mortality of patients with multiple causes
of dyspnea stratified by tertiles of pH. 12-month mortality of
patients presenting with multiple disorders responsible for acute
dyspnea (n = 114) according to tertiles of pH measured at
presentation (first tertile: pH ≤7.39, second tertile: 7.40-7.44, third
tertile: ≥7.45).
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use of ABGA in patients with this unspecific symptom
have focused on a single disorder, e.g. the diagnosis of
suspected PE. Our study measured ABGA at presenta-
tion in 530 consecutive unselected patients presenting
with acute dyspnea to the ED. We found ABGA to be
of limited value in the management of this important
group of patients in the ED. The diagnostic accuracy of
ABGA provided useful to identify patients with HV but
performed less well in other, more serious disease such
as exacerbated COPD. Accordingly, our study does not
favor measurement of ABGA as a diagnostic test in
patients presenting with dyspnea. It is however impor-
tant to recognize, that ABGA can be helpful in specific
conditions as to control O2 saturation gap between
transcutaneous oxygen saturation measurement and
arterial oxygen saturation or in certain patients with
hypoxemia.
Our study further showed that pH was the only ABGA
parameter that, independently of other factors, predicted
long-term outcome in patients presenting with acute dys-
pnea. Additionally, predictors of long-term prognosis
were previous use of oral diuretics, BMI, and more than
one cause of dyspnea. When analyzed according to the
underlying disorder, pH remained an independent pre-
dictor of 12-month mortality in both patients with pul-
monary and non-pulmonary causes of dyspnea. Patients
with acute dyspnea from multiple causes had higher
12-month mortality than patients with a single. When
analyzed according to tertiles of pH, long-term mortality
was higher only in patients in the first and second tertile,
independently increasing mortality in these patients.
Long-term outcome is affected by both the severity of
acute disease as well as comorbidity unrelated to the
acute presenting condition. In our study, among them
were factors related to the acute condition (≥2 causes of
acute dyspnea and pH) as well as factors quantifying
comorbidity (previous use of oral diuretics and BMI).
Previous studies have shown that pH is a predictor for
the need of hospitalization [16] and in-hospital outcome
[24,25] in exacerbated COPD and a predictor of in-hos-
pital mortality in pneumonia and thus is an integral part
of the clinical Pneumonia Severity Score (PSI) [26].
Recently, it was suggested that pH might also be an
indicator of long-term survival [27,28]. Our results sup-
port these findings obtained in specific patient groups.
Additionally, the present study expands the prognostic
value of pH to the important group of patients present-
ing to the ED with acute dyspnea. In elderly patients
(older than 65 years) presenting with acute respiratory
failure to the ED, hypercapnia was among other vari-
ables a significant predictor of mortality [29]. In our
cohort of unselected patients with a large majority of
them being hospitalized (87%), pH was not only a pre-
dictor for long-term mortality but also predicted ICU
admission, in-hospital mortality, and mortality after 30-
day follow up. pH at presentation may therefore serve
for the risk stratification of patients admitted for acute
dyspnea.
Arterial puncture is not only painful and carries the
risk vascular complications [30], it also may be difficult
to perform, especially in an ED setting that might lack
the calm that is needed for the procedure. Venous
blood gas analysis has been proposed as a substitute for
ABGA [31]. It has since been shown that venous pH
has excellent correlation with arterial measurement of
pH both in patients with exacerbated COPD [32,33] and
other pulmonary and non-pulmonary disorders [32,34].
To a lesser extent, a clinically useful correlation has also
been described for venous CO2 [34,35]. As expected, no
correlation exists for PaO2. Taken together, the current
evidence indicates that ABGA can be replaced by
venous measurement of blood gases in the initial evalua-
tion of patients in the ED.
Several limitations of the study should be considered.
First, the decision to perform ABGA at presentation was
exclusively at the discretion of the ED physician in charge
based on the initial assessment of the patient. We did not
use a standardized algorithm to decide if ABGA had to
be performed. It is reasonable to believe that those
patients who benefited most from ABGA were selected,
for example a higher rate of ICU admission in patients
with ABGA, and thus this bias should at least be conser-
vative. Second, our prospectively defined endpoint was
all-cause mortality. The classification of death in clinical
practice is challenging and has been shown to be often
inaccurate [36]. Third, we only examined patients with
acute dyspnea presenting to the ED. Our results therefore
Table 5 Predictors of 12-month mortality in patients with acute dyspnea (significant variables only)
Variable Hazard ratio 95% confidence interval P-value
Previous use of oral diuretics 1.93 1.15-2.86 0.006
Body mass index (per increase of 1 unit) 0.93 0.90-0.97 < 0.001
≥2 causes of dyspnea 1.91 1.22-3.00 0.003
pH (per decrease of 0.1 unit) 1.41 1.11-1.79 0.005
Models were adjusted for age, sex, New York Heart Association (NYHA) class, history of coronary artery disease, history of chronic obstructive pulmonary disease,
history of any pulmonary disease, history of chronic kidney disease, history of smoking, previous use of oral diuretics, previous use of inhaled beta agonists,
systolic blood pressure, respiration rate, body mass index, two or more causes of dyspnea, and pH at admission.
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Page 9 of 11do not negate the usefulness of ABGA in other settings,
such as the titration of supplemental oxygen in patients
with severe COPD and hypoxemia.
Conclusions
Our study shows that ABGA at presentation is of lim-
ited value in the initial assessment of patients admitted
to the ED for acute dyspnea. Used as a diagnostic para-
meter, ABGA proved not useful to distinguish between
patients with pulmonary and non-pulmonary causes of
acute dyspnea or to identify specific disorders responsi-
ble for acute dyspnea. Our study further showed that
pH measured at presentation was a predictor of short-
and long-term outcome in acutely dyspneic patients.
Both in patients with pulmonary and other causes of
acute dyspnea, the association of pH and mortality was
independent of other predictors. pH might therefore be
valuable for optimal risk stratification in this prevalent
group of patients. However, the increasing evidence on
the interchangeability of venous and arterial pH ques-
tions the need for ABGA measurement. Further pro-
spective studies with consecutive venous blood gas
analysis measurement at presentation are warranted to
assess the prognostic value of pH in venous blood
samples.
Key messages
￿ ABGA parameters at presentation varied widely
among patients with acute dyspnea.
￿ ABGA parameters were useful neither to distinguish
between patients with pulmonary disorders and other
causes of acute dyspnea nor to identify specific disorders
responsible for acute dyspnea.
￿ pH measured at presentation was a significant pre-
dictor of short- and long-term outcome in acutely dys-
pneic patient.
￿ pH was, independently from other predictors, asso-
ciated with mortality, both in patients with pulmonary
disorders and other causes of acute dyspnea.
Additional material
Additional file 1: Baseline characteristics. Baseline characteristics of
patients who received arterial blood gas analysis (ABGA) upon
presentation with acute dyspnea to the emergency department and of
patients who did not receive ABGA.
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